• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT shares jump on Q4 prelims

January 10, 2017 By Sarah Faulkner

Intersect ENT shares jump on Q4 prelimsIntersect ENT (NSDQ:XENT) shares jumped yesterday 11% to reach a peak of $13.20 apiece after the company released its preliminary financial results for the 4th quarter, narrowly beating analysts’ expectations on Wall Street.

The Menlo Park, Calif.-based company said it expects a total revenue of $24.o – $24.2 million for Q4, slightly ahead of the consensus on The Street, where analysts were looking for sales of $23.1 million.

“We are very pleased with our strong quarter and great year. Simply put – and our results bear this out – positive outcomes for chronic sinusitis patients continue to be our focus,” president & CEO Lisa Earnhardt said in prepared remarks. “Our preliminary financial results demonstrate wide acceptance of the use of our products, with now more than 150,000 patients having been treated. In addition, our product pipeline is robust with positive outcomes in both the Propel Contour and the Resolve product pivotal clinical studies. We believe our long-term goal of treating chronic sinusitis patients across the continuum of care will be realized over the next few years.”

Intersect pegged its revenue for the year somewhere between $78.5 – 78.7 million, while analysts predict it will be closer to $77.5 million.

XENT shares were trading at $12.80 apiece in mid-morning activity today, down -1.9%.

Shares in the company fell over 30% in November after the Centers for Medicare & Medicaid Services released its 2017 Hospital Outpatient Final Rule, which included reimbursement rates for sinus surgery at a fixed amount nearly 50% below the current average amount.

In October, the company’s Resolve sinus implant met both primary endpoints in the Resolve II pivotal trial. The Resolve steroid-releasing sinus implant is a minimally invasive treatment for patients with recurrent ethmoid sinus obstruction. The 300-patient Resolve II trial compared the bilateral Resolve implant with a sham procedure.

The study evaluated the change in polyp grade after 90 days using video endoscopy, showing a statistically significant reduction for patients receiving the implant. The treatment group also experienced a reduction in sense of nasal obstruction and congestion. There was a single incidence of intranasal bleeding, a serious adverse event.

Intersect said it plans to use the data to back its bid for FDA approval of the device.

Filed Under: Drug-Device Combinations, Featured, Implants, Otolaryngology Ear, Nose & Throat, Wall Street Beat Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS